TreeFrog Therapeutics: Mimicking how stem cells grow in the human body

Human iPS cell amplification in a 10-liter bioreactor © TreeFrog Therapeutics

The French biotech’s proprietory technology to cultivate pluripotent stem cells in a 3D environment can be scaled to mass-produce high-quality cells to  treat diseases such as Parkinson’s

Pluripotent stem cells are master cells that can be used to make different types of cells for various purposes. They can also self-renew and potentially produce any cell or tissue that the body needs to repair itself. In the past, human induced pluripotent stem cell (hiPSC) cultivation took place in the 2D environment of a petri dish, a laborious process that produces poor quality cells in limited quantities – a major barrier to the widespread development of stem cell therapies.French biotech startup TreeFrog Therapeutics has developed a game-changing biocapsule solution to cultivate pluripote...
Limited Reading

The rest of the content is only available if you are logged in.

Limited Reading

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By accessing and using and all pages within the domain (the “Website”), You accept and agree to have read, understood, accepted and agreed to be bound by the Terms of Use and Privacy Policy in full. If you disagree with all or any part of these Terms of Use and Privacy Policy, please do not use or continue any further use of this website. You acknowledge that you are aware that this Website contains an archive of existing content as at 31 December 2021 and is not being actively managed. We are under no obligation to update the content on this Website and, accordingly, no new content or articles will be posted to the Website after 31 December 2021.